17:18 , Apr 25, 2019 |  BC Innovations  |  Emerging Company Profile

miR Scientific: spotting aggression with RNA in urine

miR has paired its panel of urine-based RNAs with a statistical algorithm for accurate diagnosis of aggressive bladder and prostate cancers, sparing patients with lower-grade tumors from invasive biopsies and unnecessary drug treatments. The company's...
02:22 , Apr 5, 2019 |  BC Innovations  |  Tools & Techniques

Second shot for shRNA

Having long been demoted to tool compound status, shRNA is gaining renewed attention as a therapeutic modality by offering a simpler path to creating next-generation cell therapies than gene editing. Celyad has jumped in, using...
01:56 , Mar 8, 2019 |  BC Innovations  |  Targets & Mechanisms

Oral insulin innovation

While clinical data suggest an oral insulin product may finally be within reach, the technology struggles to compete with injectables on price and efficacy. A handful of academics and companies are pushing preclinical innovation in...
01:16 , Feb 27, 2018 |  BC Extra  |  Preclinical News

Mutant p53 promotes tumor growth via exosomal miR-1246

A new study from the National Institutes of Health suggests mutant p53 promotes cancer progression by creating an immunosuppressive tumor microenvironment, in addition to its known roles inside cancer cells. p53 is one of the...
01:00 , Feb 17, 2017 |  BC Innovations  |  Targets & Mechanisms

Gilding the Goldfinch

In launching Goldfinch Biopharma Inc. , Third Rock is extending its already heavy footprint in precision medicine into chronic kidney disease. The VC thinks the unfolding genetics in that field can yield disease-modifying therapies and...
08:00 , Jan 25, 2016 |  BC Week In Review  |  Clinical News

MiR-103/107: Phase I started

AstraZeneca began a single-blind, placebo-controlled, U.S. Phase I trial to evaluate single ascending doses of subcutaneous AZD4076 in about 48 healthy male volunteers. The trial start triggered a $10 million milestone payment to Regulus from...
08:00 , Dec 3, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Myosin regulatory light chain interacting protein (MYLIP; MIR; IDOL)

Neurology INDICATION: Alzheimer's disease (AD) Cell culture and mouse studies suggest inhibiting MYLIP could help treat AD. In a mouse neuronal cell line and primary mouse neurons incubated with β-amyloid 42 (Aβ42), MYLIP knockdown increased...
07:00 , Oct 26, 2015 |  BC Week In Review  |  Clinical News

Reveal G4 Rapid HIV-1 Antibody Test regulatory update

FDA approved MedMira’s Reveal G4 Rapid HIV-1 Antibody Test to detect HIV-1 antibodies in fingerstick and venipuncture whole blood. The point-of-care test uses the company’s Rapid Vertical Flow Technology for rapid analysis of samples. MedMira...
07:00 , Jun 29, 2015 |  BioCentury  |  Emerging Company Profile

Swallowing large molecules

Researchers have been working on oral delivery of peptides and antibodies for decades with limited success. Rani Therapeutics LLC is taking a different approach, with an orally delivered, pH-activated capsule that uses sugar needles to...
08:00 , Dec 4, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Atherosclerosis Myosin regulatory light chain interacting protein (MYLIP; MIR; IDOL); liver X receptor (LXR) Nonhuman primate studies suggest combining MYLIP inhibitors with LXR agonists...